💊

Setronax

Tablet

🧬 Ondansetron 🏢 Monicopharma Ltd.
Generic Name Ondansetron
Manufacturer Monicopharma Ltd.
Unit Price Unit Price: ৳ 10.00 (30's pack: ৳ 300.00)

🔹 Indications

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Pharmacology

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Dosage & Administration

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Interaction

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Contraindications

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Side Effects

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Pregnancy & Lactation

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Precautions & Warnings

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Pediatric Usage

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

🔹 Storage Conditions

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
  • Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
  • Prevention and treatment of post-operative nausea and vomiting.
  • Prevention of radiotherapy-induced nausea and vomiting.

💡 Frequently Asked Questions

Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Prevention and treatment of post-operative nausea and vomiting....
Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Prevention and treatment of post-operative nausea and vomiting....
Setronax is a serotonin subtype 3 (5-HT3) receptor antagonist indicated: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. Prevention and treatment of post-operative nausea and vomiting....

User Reviews

No reviews yet!
Be the first to share your experience.

Write a Review